Statement regarding recent speculation
(Thomson Reuters ONE) -
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in
the press and elsewhere regarding a potential acquisition of the company.
The Board confirms that it has received a preliminary and conditional non-
binding proposal in relation to a possible offer for all shares issued by the
company.
There can be no certainty that an offer will be made, nor as to the terms of any
such offer. A further announcement will be made when appropriate.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications VP, Head of Investor Relations
T:
+46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506,
+46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Sobi announces the information set out in this press release pursuant to the
Swedish Securities Market Act. The information was submitted for publication at
08:05 CET on 27 April 2015.
012e_Statement Speculation:
http://hugin.info/134557/R/1914966/684394.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1914966]
Unternehmensinformation / Kurzprofil:
Datum: 27.04.2015 - 08:06 Uhr
Sprache: Deutsch
News-ID 388533
Anzahl Zeichen: 2756
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 91 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Statement regarding recent speculation"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
